A groundbreaking DNA test may change the treatment landscape for breast cancer patients in the UK. According to a recent international study, over two-thirds of participants could avoid chemotherapy, opting instead for hormone therapy. This shift is significant, as chemotherapy often comes with severe side effects like fatigue and hair loss, impacting patients’ quality of life.
The Prosigna test evaluates the activity of genes related to breast cancer, helping doctors identify those who would benefit from chemotherapy versus those who would not. With around 5,000 NHS patients potentially avoiding chemotherapy each year, this could lead to a more personalised and less burdensome treatment approach.
For patients, the implications are profound. Many will be spared the physical and emotional toll of chemotherapy, which can linger long after treatment ends. This not only enhances their immediate wellbeing but also allows for a focus on less invasive therapies that may be equally effective.
As these findings are presented at a major cancer conference, the potential for this test to reshape breast cancer treatment in the UK is becoming clearer. It marks a significant step towards more tailored healthcare, aligning treatment with individual genetic profiles rather than relying solely on traditional methods.
Source: BBC News
